UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported):May 7, 2008
Valeant Pharmaceuticals International
(Exact name of registrant as specified in its charter)
| | | | | |
Delaware
(State or other jurisdiction of
incorporation or organization) | | 1-11397
(Commission File Number) | | 33-0628076
(I.R.S Employer
Identification No.) |
One Enterprise
Aliso Viejo, California 92656
(Address of principal executive offices) (Zip Code)
(949) 461-6000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 2.02 Results of Operations and Financial Condition
On May 7, 2008, Valeant Pharmaceuticals International (the “Company”) issued a press release announcing results of operations for the quarter ended March 31, 2008 and certain other financial information as of and for the quarter ended March 31, 2008. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference. On May 7, 2008, the Company also made available on its website (www.valeant.com) supplemental financial information for the quarterly periods ended March 31, 2007, June 30, 2007, September 30, 2007, and December 31, 2007 and the comparable periods for 2006, including certain non-GAAP financial measures. A copy of the information posted on the website is attached as Exhibit 99.2 to this report and is incorporated herein by this reference.
The information in this Item 2.02, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and Exhibits 99.1 and 99.2 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| 99.1 | | Press release dated May 7, 2008. |
| |
| 99.2 | | Information made available on the Company’s website on May 7, 2008. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | VALEANT PHARMACEUTICALS INTERNATIONAL
| |
| Date: May 7, 2008 | By: | /s/ Peter J. Blott | |
| | | Peter J. Blott | |
| | | Executive Vice President
and Chief Financial Officer | |
INDEX TO EXHIBITS
| 99.1 | | Press release dated May 7, 2008. |
| |
| 99.2 | | Information made available on the Company’s website on May 7, 2008. |
